Table 6.
Cancer type | Stage | NEU1 | ST3GAL1 | ST3GAL5 | CMAS | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
R2 | MT | TF | R2 | MT | TF | R2 | MT | TF | R2 | MT | TF | ||
BLCA | Normal | 0.98 | 0.0% | 100.0% | 0.66 | 0.0% | 100.0% | 1.00 | 79.6% | 20.4% | – | – | – |
BLCA | Stage II | 0.51 | 12.7% | 87.3% | 0.77 | 48.0% | 52.0% | 0.89 | 46.3% | 53.7% | 0.85 | 10.7% | 89.3% |
BLCA | Stage III | 0.72 | 44.5% | 55.5% | 0.70 | 51.0% | 49.0% | 0.72 | 39.2% | 60.8% | 0.75 | 32.6% | 67.4% |
BLCA | Stage IV | 0.92 | 33.9% | 66.1% | 0.88 | 52.1% | 47.9% | 0.65 | 33.8% | 66.2% | 0.79 | 36.5% | 63.5% |
BRCA | Normal | 0.80 | 0.0% | 100.0% | 0.96 | 28.9% | 71.1% | 0.71 | 0.0% | 100.0% | 0.92 | 1.2% | 98.8% |
BRCA | Stage I | 0.76 | 48.1% | 51.9% | 0.83 | 74.4% | 25.6% | 0.64 | 13.5% | 86.5% | 0.47 | 0.0% | 100.0% |
BRCA | Stage II | 0.48 | 21.0% | 79.0% | 0.63 | 62.3% | 37.7% | 0.40 | 40.1% | 59.9% | 0.60 | 37.4% | 62.6% |
BRCA | Stage III | 0.37 | 44.8% | 55.2% | 0.70 | 61.0% | 39.0% | 0.63 | 19.9% | 80.1% | 0.68 | 13.3% | 86.7% |
COAD | Normal | 0.91 | 47.6% | 52.4% | 0.76 | 0.0% | 100.0% | 1.00 | 14.1% | 85.9% | 0.96 | 21.8% | 78.2% |
COAD | Stage I | 0.87 | 58.1% | 41.9% | 0.72 | 86.8% | 13.2% | 0.88 | 13.9% | 86.1% | 0.78 | 49.2% | 50.8% |
COAD | Stage II | 0.69 | 52.9% | 47.1% | 0.73 | 64.4% | 35.6% | 0.77 | 30.5% | 69.5% | 0.82 | 21.4% | 78.6% |
COAD | Stage III | 0.95 | 32.9% | 67.1% | 0.78 | 48.8% | 51.2% | 0.69 | 26.4% | 73.6% | 0.60 | 28.7% | 71.3% |
COAD | Stage IV | 0.98 | 38.0% | 62.0% | 0.37 | 100.0% | 0.0% | 0.85 | 26.0% | 74.0% | – | – | – |
HNSC | Normal | 1.00 | 53.1% | 46.9% | 0.96 | 89.6% | 10.4% | 0.96 | 46.4% | 53.6% | 0.84 | 24.9% | 75.1% |
HNSC | Stage I | 1.00 | 85.9% | 14.1% | 0.88 | 68.1% | 31.9% | 0.96 | 30.8% | 69.2% | 0.24 | 100.0% | 0.0% |
HNSC | Stage II | 0.43 | 57.9% | 42.1% | 0.66 | 49.2% | 50.8% | 0.91 | 39.4% | 60.6% | 0.84 | 32.4% | 67.6% |
HNSC | Stage III | 0.84 | 80.3% | 19.7% | 0.73 | 37.9% | 62.1% | 0.84 | 30.7% | 69.3% | 0.27 | 100.0% | 0.0% |
HNSC | Stage IV | 0.73 | 15.2% | 84.8% | 0.83 | 57.9% | 42.1% | 0.58 | 26.5% | 73.5% | 0.83 | 33.1% | 66.9% |
LUAD | Normal | 1.00 | 61.5% | 38.5% | 1.00 | 43.1% | 56.9% | 1.00 | 13.7% | 86.3% | 0.84 | 0.0% | 100.0% |
LUAD | Stage I | 0.82 | 42.2% | 57.8% | 0.76 | 61.5% | 38.5% | 0.68 | 33.7% | 66.3% | 0.67 | 18.5% | 81.5% |
LUAD | Stage II | 0.88 | 38.4% | 61.6% | 0.57 | 41.7% | 58.3% | 0.67 | 34.9% | 65.1% | 0.82 | 15.7% | 84.3% |
LUAD | Stage III | 0.75 | 82.2% | 17.8% | 0.90 | 67.8% | 32.2% | 0.84 | 34.8% | 65.2% | 1.00 | 25.3% | 74.7% |
LUAD | Stage IV | – | – | – | 1.00 | 73.0% | 27.0% | 0.97 | 84.1% | 15.9% | 0.49 | 0.0% | 100.0% |
LUSC | Normal | – | – | – | 0.95 | 0.0% | 100.0% | 1.00 | 0.0% | 100.0% | 1.00 | 0.0% | 100.0% |
LUSC | Stage I | 0.84 | 37.5% | 62.5% | 0.75 | 59.5% | 40.5% | 0.79 | 27.6% | 72.4% | 0.86 | 13.8% | 86.2% |
LUSC | Stage II | 0.26 | 37.8% | 62.2% | 0.73 | 38.3% | 61.7% | 0.54 | 59.5% | 40.5% | 0.52 | 30.1% | 69.9% |
LUSC | Stage III | 0.64 | 65.4% | 34.6% | 0.62 | 73.3% | 26.7% | 0.84 | 41.3% | 58.7% | – | – | – |
PAAD | Normal | 0.98 | 0.0% | 100.0% | 1.00 | 100.0% | 0.0% | 1.00 | 0.0% | 100.0% | 1.00 | 0.0% | 100.0% |
PAAD | Stage I | 0.78 | 83.8% | 16.2% | 0.98 | 75.1% | 24.9% | – | – | – | 0.96 | 3.2% | 96.8% |
PAAD | Stage II | 0.73 | 48.1% | 51.9% | 0.78 | 36.4% | 63.6% | 0.61 | 32.6% | 67.4% | 0.79 | 8.3% | 91.7% |
STAD | Stage I | 0.44 | 0.0% | 100.0% | 0.57 | 59.1% | 40.9% | 0.79 | 34.6% | 65.4% | 0.47 | 78.0% | 22.0% |
STAD | Stage II | 0.92 | 82.8% | 17.2% | 0.58 | 49.5% | 50.5% | 0.86 | 38.4% | 61.6% | 0.86 | 9.6% | 90.4% |
STAD | Stage III | 0.90 | 58.3% | 41.7% | 0.54 | 81.7% | 18.3% | 0.77 | 9.2% | 90.8% | 0.76 | 62.9% | 37.1% |
STAD | Stage IV | 1.00 | 78.0% | 22.0% | 0.84 | 69.4% | 30.6% | 0.98 | 51.3% | 48.7% | 0.99 | 13.2% | 86.8% |
Groups with fewer than 20 samples were dropped and marked using “–”. The percentage shown in columns MT and TF are relative sum of squares (see section Methods).